HomeProductsBioactive CompoundsCell CycleDNA/RNA SynthesisVidofludimus
Chemical structure of CAS 717824-30-1

Vidofludimus

CAS No.717824-30-1
MDL No.MFCD18633262
MFC20H18FNO4
MW355.40
InChI KeyXPRDUGXOWVXZLL-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.717824-30-1
Product NameVidofludimus

Biological Targets

DHODH

Associated Conditions

rheumatoid arthritis·COVID-19·multiple sclerosis·sclerosing cholangitis·inflammatory bowel disease·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.

Multiple sclerosis and related disorders • Vol. 43 • 2020
PMID: 32428844DOI: 10.1016/j.msard.2020.102129

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.

European journal of drug metabolism and pharmacokinetics • Vol. 45, Issue 5 • 2020
PMID: 32361977PMC: PMC7511286DOI: 10.1007/s13318-020-00623-7

Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.

Journal of Crohn's & colitis • Vol. 7, Issue 8 • 2013
PMID: 23078909DOI: 10.1016/j.crohns.2012.09.016

Documentation

Similar Products